The mass of regenerating tissues, such as bone, is critically dependent on the number of executive cells, which in turn is determined by the rate of replication of progenitors and the life-span of mature cells, reflecting the timing of death by apoptosis. Bone mass can be increased by intermittent parathyroid hormone (PTH) administration, but the mechanism of this phenomenon has remained unknown. We report that daily PTH injections in mice with either normal bone mass or osteopenia due to defective osteoblastogenesis increased bone formation without affecting the generation of new osteoblasts. Instead, PTH increased the life-span of mature osteoblasts by preventing their apoptosis — the fate of the majority of these cells under normal conditions. The antiapoptotic effect of PTH was sufficient to account for the increase in bone mass, and was confirmed in vitro using rodent and human osteoblasts and osteocytes. This evidence provides proof of the basic principle that the work performed by a cell population can be increased by suppression of apoptosis. Moreover, it suggests novel pharmacotherapeutic strategies for osteoporosis and, perhaps, other pathologic conditions in which tissue mass diminution has compromised functional integrity.
Robert L. Jilka, Robert S. Weinstein, Teresita Bellido, Paula Roberson, A. Michael Parfitt, Stavros C. Manolagas
Title and authors | Publication | Year |
---|---|---|
Building bone to reverse osteoporosis and repair fractures
Sundeep Khosla, Jennifer J. Westendorf, and Merry Jo Oursler |
Journal of Clinical Investigation | 2008 |
Control of bone mass and remodeling by PTH receptor signaling in osteocytes
CA O'Brien, LI Plotkin, C Galli, JJ Goellner, AR Gortazar, MR Allen, AG Robling, M Bouxsein, E Schipani, CH Turner, RL Jilka, RS Weinstein, SC Manolagas, T Bellido |
PloS one | 2008 |
Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis
TJ Martin, NA Sims, KW Ng |
Osteoporosis International | 2008 |
Granulocyte colony-stimulating factor induces osteoblast apoptosis and inhibits osteoblast differentiation
MJ Christopher, DC Link |
Journal of Bone and Mineral Research | 2008 |
Osteoporosis
JJ Westendorf |
Osteoporosis International | 2008 |
Osteoporosis
JJ Westendorf |
Osteoporosis International | 2008 |
Osteoporosis
JJ Westendorf |
Osteoporosis International | 2008 |
Osteoporosis
JJ Westendorf |
Osteoporosis International | 2008 |
Osteoporosis
JJ Westendorf |
Osteoporosis International | 2008 |
Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration
M Ogita, MT Rached, E Dworakowski, JP Bilezikian, S Kousteni |
Endocrinology | 2008 |
Mechanisms of the Anabolic Effects of Teriparatide on Bone: Insight From the Treatment of a Patient With Pycnodysostosis
P Chavassieux, MA Karsdal, T Segovia-Silvestre, AV Neutzsky-Wulff, R Chapurlat, G Boivin, PD Delmas |
Journal of Bone and Mineral Research | 2008 |
Bim, Bak, and Bax Regulate Osteoblast Survival
M Liang, G Russell, PA Hulley |
Journal of Bone and Mineral Research | 2008 |
Combination Therapy Using Exercise and Pharmaceutical Agents to Optimize Bone Health
RK Fuchs, SJ Warden |
Clinical Reviews in Bone and Mineral Metabolism | 2008 |
Formulations for Intermittent Release of Parathyroid Hormone (1-34) and Local Enhancement of Osteoblast Activities
JH Jeon, DA Puleo |
Pharmaceutical Development and Technology | 2008 |
IL-6 receptor expression and IL-6 effects change during osteoblast differentiation
Y Li, CM Bäckesjö, LA Haldosén, U Lindgren |
Cytokine | 2008 |
The anabolic response to parathyroid hormone is augmented in Rac2 knockout mice
T Kawano, N Troiano, DJ Adams, JJ Wu, B Sun, K Insogna |
Endocrinology | 2008 |
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo
LI Plotkin, V Lezcano, J Thostenson, RS Weinstein, SC Manolagas, T Bellido |
Journal of Bone and Mineral Research | 2008 |
Hyperlipidemia impairs osteoanabolic effects of PTH
MS Huang, J Lu, Y Ivanov, AP Sage, W Tseng, LL Demer, Y Tintut |
Journal of Bone and Mineral Research | 2008 |
Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
C Gagnon, V Li, PR Ebeling |
Clinical Interventions in Aging | 2008 |
Cancer treatment-related bone loss: a review and synthesis of the literature
MN Khan, AA Khan |
Current oncology (Toronto, Ont.) | 2008 |
Clinical significance of HIV-associated bone loss: when and how to intervene
MT Yin, E Shane, K Anastos |
Future HIV Therapy | 2008 |
Influence of host periosteum and recipient bed perforation on the healing of onlay mandibular bone graft: an experimental pilot study in the sheep
WL Adeyemo, T Reuther, W Bloch, Y Korkmaz, JH Fischer, JE Zöller, AC Kuebler |
Oral and Maxillofacial Surgery | 2008 |
Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2
V Alonso, AR de Gortázar, JA Ardura, I Andrade-Zapata, MV Alvarez-Arroyo, P Esbrit |
Journal of Cellular Physiology | 2008 |
Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption
NA Sims, JH Gooi |
Seminars in Cell & Developmental Biology | 2008 |
Effect of progesterone on apoptosis of murine MC3T3-E1 osteoblastic cells
QP Wang, H Xie, LQ Yuan, XH Luo, H Li, D Wang, P Meng, EY Liao |
Amino Acids | 2008 |
On the Interpretation of Rat Carcinogenicity Studies for Human PTH(1-34) and Human PTH(1-84)
AH Tashjian, D Goltzman |
Journal of Bone and Mineral Research | 2008 |
Bone-forming agents in the management of osteoporosis
A Neuprez, JY Reginster |
Best Practice & Research Clinical Endocrinology & Metabolism | 2008 |
Effect of Teriparatide on Early Bone Loss After Kidney Transplantation
D Cejka, T Benesch, C Krestan, P Roschger, K Klaushofer, P Pietschmann, M Haas |
American Journal of Transplantation | 2008 |
Species difference exists in the effects of 1α,25(OH)2D3 and its analogue 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 (2MD) on osteoblastic cells
Y Li, CM Bäckesjö, LA Haldosén, U Lindgren |
The Journal of Steroid Biochemistry and Molecular Biology | 2008 |
Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion
H Galitzer, I Ben-Dov, V Lavi-Moshayoff, T Naveh-Many, J Silver |
Current Opinion in Nephrology and Hypertension | 2008 |
Osteocytes in the pathogenesis of osteoporosis
K Ikeda |
Geriatrics & Gerontology International | 2008 |
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
BL Clarke |
Yearbook of Endocrinology | 2008 |
Hypoparathyroidism
D Shoback |
New England Journal of Medicine | 2008 |
Human Parathyroid Hormone 1–34 Prevents Bone Loss in Experimental Biliary Cirrhosis in Rats
R Dresner–Pollak, Y Gabet, A Steimatzky, G Hamdani, I Bab, Z Ackerman, M Weinreb |
Gastroenterology | 2008 |
Principles of Bone Biology
CJ Rosen, T Niu |
Principles of Bone Biology | 2008 |
Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone
D Goltzman |
Archives of Biochemistry and Biophysics | 2008 |
Teriparatide in the treatment of osteoporosis
J Stroup, MP Kane, AM Abu-Baker |
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists | 2008 |
Genomics in Endocrinology
S Handwerger, B Aronow |
2008 |